Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance
May 4, 2023 8:21 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.
GUIDANCE:
Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of... More
